<DOC>
	<DOCNO>NCT01006798</DOCNO>
	<brief_summary>The purpose study compare safety immunogenicity 9-month period five different dosage Ad4-H5-Vtn volunteer ( Vaccinees ) receive three dos study vaccine placebo . In addition , transmission Ad4-H5-Vtn evaluate Household Contacts reside vaccinated volunteer . Vaccinees also may participate substudy receive booster vaccination license Influenza Virus Vaccine , H5N1 ( Sanofi Pasteur ) .</brief_summary>
	<brief_title>Safety Immunogenicity Replication-Competent Adenovirus 4-vectored Vaccine Avian Influenza H5N1</brief_title>
	<detailed_description>At least 160 healthy Vaccinees randomize 5 ascend dosage cohort consist least 32 volunteer . In dosage cohort Vaccinees randomly assign receive 3 dos either Ad4-H5-Vtn placebo separate approximately 56 day . Volunteers follow 168 day post-third vaccination .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adult healthy adult household contact . Healthcare worker direct contact patient immunodeficient , HIVpositive , unstable medical condition , age 18 . Childcare worker direct contact child 5 year old young . Resides Household Contacts age 18 age 65 . Received plan receive license inactivated 2009 H1N1 influenza vaccine 14 day prior 14 day study vaccination . Received plan receive license vaccine 30 day prior first study vaccination 30 day third study vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Virus Diseases</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
	<keyword>Vaccine</keyword>
</DOC>